Multiple Sclerosis Walking Scale-12 (MSWS-12)
- Introduced by
- Jeremy C. Hobart, University of Plymouth
- Year
- 2003
- Type
- Self-report questionnaire
- Family
- disease-specific walking disability
What does it do?
The MSWS-12 is a brief, patient-reported outcome measure specifically designed to assess the impact of multiple sclerosis on walking ability and limitation.
Developed by Hobart and colleagues in 2003, this 12-item scale captures both the physical difficulty and functional consequences of MS-related gait impairment. It is highly responsive to change and widely used in MS clinical trials and practice as a primary outcome measure for assessing intervention effects on mobility.
The intuition behind the method
Walking difficulty is one of the most common and functionally disabling symptoms in multiple sclerosis, often cited by patients as a primary concern affecting quality of life and independence. While objective measures like the Timed 25-Foot Walk test measure gait speed, they do not capture patient-perceived difficulty, limitations in walking distance or context, or psychological impact of mobility restriction. MSWS-12 directly measures how MS walking impairment affects activities and participation—how far the patient can walk, confidence in balance, environmental barriers, and fear of falls. This patient-centered approach reveals that perceived walking limitation is not simply a function of objective gait speed; some patients with objectively slow gait adapt well, while others with milder speed reduction report substantial limitation due to fatigue, confidence, or psychological distress.
History
MSWS-12 was developed by Jeremy Hobart at the University of Plymouth in 2003 as a response to the need for a brief, sensitive, patient-reported measure of MS walking limitation. It was rigorously developed through item reduction from a larger item pool and psychometric testing in large MS cohorts. The scale was published in Neurology and quickly adopted as a standard outcome in MS research. Its brevity and responsiveness made it particularly valuable for clinical practice and large-scale trials. MSWS-12 has been translated and validated in 25+ languages and is recommended by MS professional societies. No major revisions have been published; the original 12-item version remains standard.
When to use it
MSWS-12 is ideal when brief assessment of MS walking impact is needed: clinical trials of therapies targeting mobility (rehabilitation, exercise, walking-specific treatments), routine clinical monitoring in MS clinics to track walking-related disability, longitudinal cohort studies examining predictors of walking decline, comparative effectiveness research of mobility interventions, and patient-reported outcomes surveillance. It complements objective gait measures (Timed 25-Foot Walk, 6-Minute Walk Test) by capturing subjective walking experience. It is less suitable when non-walking MS patients must be assessed (use broader QoL scales like MSQOL-54 instead) or when only objective gait speed is the outcome of interest.
Limitations and considerations
- Scores range 0-100 with higher=worse, which is opposite to most QoL scales and can be counterintuitive; scoring transformation must be applied correctly
- Not suitable for non-ambulatory MS patients (cannot walk at baseline); does not measure wheelchair/assistive device use experience
- May show ceiling effect in very early MS with minimal walking limitation (many score near 0)
- Unidimensional structure means it does not differentiate causes of limitation (e.g., weakness vs. spasticity vs. fatigue); supplements with targeted examination needed
Source conditions do not replace independent scientific review or validation by an analysis engine.
Strengths
- Extremely brief (12 items, 3-5 minutes) and practical for routine clinical use and serial monitoring without substantial respondent burden
- Highly responsive to change—sensitive to detecting meaningful improvements in walking with rehabilitation or treatment
- Strong psychometric properties: demonstrated validity, reliability, and minimal floor/ceiling effects in diverse MS populations across disease courses
- Patient-centered measurement captures subjective walking experience and functional limitation beyond objective gait speed
- Widely adopted in MS research and clinical practice worldwide; extensively translated and validated in multiple languages
Applications
- Clinical trials of mobility interventions (physical therapy, robotic-assisted walking, pharmacological treatments for spasticity) to measure patient-perceived walking improvement as primary outcome
- Routine clinical monitoring in MS clinics to track walking limitation over time and guide rehabilitation referral decisions
- Longitudinal outcome studies examining natural history of MS walking disability, prognostic factors, and relationship between walking limitation and overall QoL
- Comparative effectiveness research evaluating different rehabilitation modalities (in-person vs. telehealth, group vs. individual therapy, intensity variations)
- Patient-reported outcomes registries and real-world effectiveness studies capturing MS walking experience in community and home settings
How it works
How it works
MSWS-12 is a self-administered questionnaire containing 12 items presented with a 1-5 Likert response scale (1='Not at all' to 5='Extremely'). Items ask about walking limitations, confidence, and difficulty in various contexts. Administration time is approximately 3-5 minutes. The patient completes the questionnaire without time pressure. No clinical training is required for administration; it can be completed on paper, electronically, or verbally if motor impairment prevents writing. Suitable for patients with MS diagnosis and ambulatory ability (can walk at least short distances, though use of aids is acceptable).
Responses are summed across all 12 items, each scored 1-5. The raw total ranges from 12-60. This raw score is then transformed to a 0-100 scale using the formula: [(raw score - 12) / 48] × 100. Thus the final MSWS-12 score ranges from 0-100, with higher scores indicating greater walking limitation (counterintuitive to many QoL scales where higher=better). Some authors report the raw 12-60 scale; ensure consistency in reporting. Subscales are not typically calculated; the scale is interpreted as a unidimensional measure of MS walking impact.
MSWS-12 scores range from 0-100, with higher scores indicating more severe walking limitation. Score interpretation: 0-20 = minimal walking limitation, 21-40 = mild-moderate limitation, 41-60 = moderate-severe limitation, 61-80 = severe limitation, 81-100 = very severe limitation. There is no single clinical cutoff; interpretation is comparative: within-patient change (improvement or deterioration), between-group comparison (treatment effect in trials), or benchmarking against reference populations. A change of 4-5 points is considered minimal clinically important difference (MCID) on the 0-100 scale. The scale is highly responsive, showing meaningful change within weeks to months of intervention.
Common pitfalls
- Do not forget to transform raw scores (12-60) to the 0-100 scale using the published formula; reporting raw scores without transformation causes confusion
- Do not misinterpret high scores as good—MSWS-12 is inverted: high scores = more limitation, low scores = less limitation. This is opposite to MSQOL-54 and many other QoL measures
- Avoid administering to patients unable to walk at baseline; the scale measures walking limitation experience, not overall mobility in wheelchair users
- Do not use MSWS-12 as a substitute for objective gait measures; it complements but does not replace Timed 25-Foot Walk or other performance-based testing
Frequently asked questions
Does a high MSWS-12 score mean good walking or bad walking?
High MSWS-12 score means WORSE walking limitation. On the 0-100 scale, 0-20 = minimal limitation (good), 81-100 = very severe limitation (bad). This is opposite to most QoL scales (e.g., MSQOL-54, SF-36) where high=better. Always check the scale direction when comparing measures.
How much MSWS-12 change is clinically meaningful?
A change of 4-5 points on the 0-100 scale is considered the minimal clinically important difference (MCID). So an improvement (decrease) from baseline 50 to 45 is meaningful; a change to 48 might not be. In clinical trials, effect sizes and between-group differences are more informative than individual point changes.
Should I use MSWS-12 or Timed 25-Foot Walk test?
MSWS-12 measures patient-perceived walking limitation; Timed 25-Foot Walk measures objective gait speed. Both are valuable and often used together: T25FW for objective impairment, MSWS-12 for subjective impact. Some patients with slow gait report minimal limitation; others with faster gait report substantial limitation. Both capture important aspects. Use MSWS-12 for clinical monitoring of QoL impact; use T25FW to objectively track gait speed changes.
Can MSWS-12 be used in wheelchair-using MS patients?
No. MSWS-12 measures walking limitation experience and is designed for patients who walk (with or without assistive devices). For non-ambulatory patients, use broader MS QoL scales (MSQOL-54) or wheelchair-specific mobility measures. If a patient transitions from walking to wheelchair during longitudinal follow-up, MSWS-12 becomes inapplicable after that transition; switch to alternative measures at that point.
Related methods
Sources
Hobart, J. C., Riazi, A., Lamping, D. L., Fitzpatrick, R., & Thompson, A. J. (2003). Measuring the impact of MS on walking ability: The 12-Item MS Walking Scale (MSWS-12). Neurology, 60(1), 31-36.
Open DOI referenceCopied.